Data showing how Repeated Lumbar Punctures within 3 days may affect CSF Biomarker Levels
As an extension of a study on the relationship between sleep deprivation and cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease, we performed two Lumbar punctures (LPs) within three days in 13 healthy volunteers (N=13). Our aim was to investigate CSF biomarker dynamics in relation to sleep deprivation. An unexpected sharp rise in biomarker concentrations in the second sample made us consider an artifact and we therefore repeated the experiment, but without sleep restriction, in four additional individuals (N=4). A similar rise in biomarker levels were evident, suggesting an inherent methodological problem with repeated LPs. Experiment 1: Repeated lumbar punctures within 3 days without sleep intervention. Participants with controled normal sleep. Biomarker concentrations from each individual lumbar puncture. Experiment 2: After sleep deprivation and 3 days later, after recovery sleep. Biomarker concentrations from each individual lumbar puncture. First puncture immediately after sleep deprivation. Second puncture three days later, after recovery sleep.
Olsson M, Arlig J, Hedner J, Blennow K, Zetterberg H. Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. Sleep. 2018;41(5). https://doi.org/10.1093/sleep/zsy025
Olsson, M., Ärlig, J., Hedner, J. et al. Repeated lumbar punctures within 3 days may affect CSF biomarker levels. Fluids Barriers CNS 16, 37 (2019) doi:10.1186/s12987-019-0157-2
Institute of Neuroscience and Physiology
A watery fluid that is continuously produced in the CHOROID PLEXUS and circulates around the surface of the BRAIN; SPINAL CORD; and in the CEREBRAL VENTRICLES.
Proteins in the cerebrospinal fluid, normally albumin and globulin present in the ratio of 8 to 1. Increases in protein levels are of diagnostic value in neurological diseases. (Brain and Bannister's Clinical Neurology, 7th ed, p221)
Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
data/Recovery sleep LP biomarker data.xlsx